According to a prominent sell-side analyst who follows MNTA, every sell-side analyst on Wall Street understands that Teva’s Lovenox is DoA, but these analysts are unwilling to say so in print for fear of losing IB business from Teva.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”